Halozyme Slides On Potential Revenue Pressure Concerns -- Market Talk

Dow Jones

May 14, 2025

1409 ET - Halozyme Therapeutics slides 24% following a downgrade to underperform from market perform at Leerink Partners, which says the Centers for Medicare and Medicaid Services issued draft guidance that could be interpreted to mean Halozyme's Enhanze drug delivery product based on recombinant human hyaluronidase may not represent a new drug but rather just an extension of the old drug. Benchmark's Robert Wasserman says it could mean "these drugs could be under consideration for price negotiations much sooner than previously thought." Before any of that can happen though, Wasserman says CMS would have to identify hyaluronidase under its costly drug category, but the manufacturer could appeal that decision. These processes have historically moved slowly, he adds.(katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

May 13, 2025 14:10 ET (18:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535096088"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535096088\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535096088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 02:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535096088","market":"nz","top_or_hot":-1,"title":"Halozyme Slides On Potential Revenue Pressure Concerns -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1409 ET - Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> slides 24% following a downgrade to underperform from market perform at Leerink Partners, which says the Centers for Medicare and Medicaid Services issued draft guidance that could be interpreted to mean Halozyme's Enhanze drug delivery product based on recombinant human hyaluronidase may not represent a new drug but rather just an extension of the old drug. Benchmark's Robert Wasserman says it could mean \"these drugs could be under consideration for price negotiations much sooner than previously thought.\" Before any of that can happen though, Wasserman says CMS would have to identify hyaluronidase under its costly drug category, but the manufacturer could appeal that decision. These processes have historically moved slowly, he adds.(katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Halozyme Slides On Potential Revenue Pressure Concerns -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHalozyme Slides On Potential Revenue Pressure Concerns -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-14 02:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1409 ET - Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> slides 24% following a downgrade to underperform from market perform at Leerink Partners, which says the Centers for Medicare and Medicaid Services issued draft guidance that could be interpreted to mean Halozyme's Enhanze drug delivery product based on recombinant human hyaluronidase may not represent a new drug but rather just an extension of the old drug. Benchmark's Robert Wasserman says it could mean \"these drugs could be under consideration for price negotiations much sooner than previously thought.\" Before any of that can happen though, Wasserman says CMS would have to identify hyaluronidase under its costly drug category, but the manufacturer could appeal that decision. These processes have historically moved slowly, he adds.(katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 14:10 ET (18:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535096088","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535096088","pubTimestamp":1747159800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1409 ET - Halozyme Therapeutics slides 24% following a downgrade to underperform from market perform at Leerink Partners, which says the Centers for Medicare and Medicaid Services issued draft guidance that could be interpreted to mean Halozyme's Enhanze drug delivery product based on recombinant human hyaluronidase may not represent a new drug but rather just an extension of the old drug. Benchmark's Robert Wasserman says it could mean \"these drugs could be under consideration for price negotiations much sooner than previously thought.\" Before any of that can happen though, Wasserman says CMS would have to identify hyaluronidase under its costly drug category, but the manufacturer could appeal that decision. These processes have historically moved slowly, he adds.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"Halozyme因潜在收入压力担忧而下滑——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":0.9},"content_text":"1409 ET - Halozyme Therapeutics slides 24% following a downgrade to underperform from market perform at Leerink Partners, which says the Centers for Medicare and Medicaid Services issued draft guidance that could be interpreted to mean Halozyme's Enhanze drug delivery product based on recombinant human hyaluronidase may not represent a new drug but rather just an extension of the old drug. Benchmark's Robert Wasserman says it could mean \"these drugs could be under consideration for price negotiations much sooner than previously thought.\" Before any of that can happen though, Wasserman says CMS would have to identify hyaluronidase under its costly drug category, but the manufacturer could appeal that decision. These processes have historically moved slowly, he adds.(katherine.hamilton@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 14:10 ET (18:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}